Austin-based Luminex Corporation yesterday announced that xMAP(R) Technology is playing a key role in the biobank profiling research within the Human Protein Atlas (HPA) project. In the latest release of the protein atlas, the HPA announced coverage of over 80% of the human protein-coding genes and RNA expression data for more than 90% of the genes.
Human Protein Atlas project’s goal is to explore the entirety of the human proteome using antibody-based proteomics. This pioneering project leverages Luminex’s xMAP Technology for biobank research of body fluids. The high-throughput biomarker screening approach combines Luminex technology with several thousand antibodies through multiplexed screening of over 380 targets per well per run.
Patrick Balthrop, president and CEO of Luminex, says to be excited to be part of “this revolutionary systematic exploration of the next frontier in human biology, the human proteome”. As Balthrop explains, the project goes beyond the genome, in order to advance the understanding of human disease and cell function. “We look forward to continuing to partner on these groundbreaking projects that advance research by developing products that help scientists make discoveries, and advance science to ultimately improve the health and quality of life for all.”
In addition to their own research, Luminex collaborates with partners to identify interesting candidate biomarkers for a wide range of diseases, says Jochen Schwenk, Ph.D., Associate Professor of Translational Proteomics at KTH Royal Institute of Technology and facility manager at the Science for Life Laboratory. “The Luminex xMAP Technology has made it possible for us to perform truly flexible and very high-throughput screening of biomarkers using the HPA antibodies on large numbers of samples. We then develop downstream biomarker validation assays on the same xMAP Technology.”
About the Human Protein Atlas project
The Human Protein Atlas started as a small research project at KTH Royal Institute of Technology in the research group of Professor Mathias Uhlen in 2000. Since 2003, the non-profit Knut and Alice Wallenberg Foundation has been the major funding agency for this project involving more than 150 scientists in 17 countries. The protein atlas utilizes antibody-based proteomics to achieve a systematic exploration and subsequent mapping of the human proteome. The project includes a publically available portal for researchers in life sciences and provides access to protein profiling data in 46 normal tissues, 20 cancer tissues and 46 cell lines on a subcellular level.
About Science for Life Laboratory
A Swedish national center for molecular biosciences, Science for Life Laboratory (SciLifeLab) focuses on health and environmental research. The center combines frontline technical expertise with advanced knowledge of translational medicine and molecular bioscience. Established in 2010 and appointed a national center in 2013 by the Swedish government, SciLifeLab is a joint effort between four Swedish universities (Karolinska Institutet, KTH Royal Institute of Technology, Stockholm University and Uppsala University). More than 200 research groups are associated with SciLifeLab, which is situated at two nodes in Stockholm and Uppsala.
About Luminex Corporation
Founded in 1995 and headquartered in Austin, Texas, Luminex Corporation engages in the development, manufacture, and sale of proprietary biological testing technologies and products for the life sciences and diagnostic industries.